Byondis
Pharmaceutical Manufacturing • 
Nijmegen, Gelderland, Netherlands • 201-500 Employees
Company overview
| Headquarters | Microweg 4, NIJMEGEN, 6545CM, NL |
| Phone number | +31246795100 |
| Website | |
| NAICS | 3254 |
| SIC | 2834, 283 |
| Keywords | Biotechnology, Oncology, CMC, Manufacturing, Biopharmaceuticals, DSP, Chemistry, Cancer, Gmp Manufacturing, USP, Adcs, Immuno-Oncology, Pharmacology, Mabs, Autoimmune, Breastcancer, Linker-Drug Technology, Medicinal & Protein Chemistry, Biomarker Development & Discovery, Drug Metabolism & Pharmacokinetics, Manufacturing And Controls |
| Founded | 2012 |
| Employees | 201-500 |
| Socials |
Key Contacts at Byondis
Declan Nolan
Director, Strategic Business Initiatives
Suzanne Van Gerwen
Director Business Development
Ivo Grgic
Senior Director Business Development & Licensing
Robert Kingma
Director Operations
Eric Van Hooren
Senior Director Clinical Development
Miranda Van Der Lee
Senior Director In Vitro Pharmacology
Bram De Kruijff
Executive Vice President / Site Director / Member Of The Board
Marga Gunnewijk
Director Cmc Project Management
Ronald Smulders
Senior Director Quality Assurance
Willem Klaassen
Director Clinical Development
Byondis Email Formats
Byondis uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@byondis.com), used 60.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@byondis.com | 60.2% |
{first initial}.{last name} | j.doe@byondis.com | 36.2% |
{first initial}.{second initial}{last name} | j.odoe@byondis.com | 3.6% |
About Byondis
Driven to improve patients’ lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics. Byondis’ broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis’ expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis’ expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house. The company has a dedicated team of more than 300 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. For more information visit www.byondis.com.
Byondis revenue & valuation
| Annual revenue | $285,000,000 |
| Revenue per employee | $987,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $912,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Byondis has 127 employees across 10 departments.
Departments
Number of employees
Funding Data
Byondis has never raised funding before.
Byondis Tech Stack
Discover the technologies and tools that power Byondis's digital infrastructure, from frameworks to analytics platforms.
Security
Miscellaneous
JavaScript libraries
JavaScript libraries
Maps
JavaScript libraries
Web servers
JavaScript libraries
Security
Analytics
United States
Germany
Canada
United Kingdom
Frequently asked questions
4.8
40,000 users
